Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liquid bone healer could replace grafts for dental implants

NCT ID NCT07707388

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether a liquid called Theravex can improve healing and stability when a dental implant is placed right after a tooth is pulled. Theravex is applied directly into the gap between the implant and the bone socket to stimulate bone growth. Researchers compare it to a standard bone graft and a combination of both in 30 people needing a front tooth implant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a bone bioactive liquid called Theravex, applied directly to the implant site to stimulate bone healing
What this could lead to
If successful, Theravex could offer a simpler, faster-healing alternative to traditional bone grafts for dental implants.
What could go wrong
This is a small, early-stage trial with only 30 participants, so results may not apply to everyone. Theravex is new and its long-term benefits over standard grafts are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient requires extraction of a single failing or non-restorable maxillary anterior tooth or premolar. * Presence of an intact buccal bone plate (Socket Type I) with a horizontal peri-implant jumping gap ≥ 2 mm. * The implant can be placed in an ideal 3-D position with an intraoperative primary stability target of ≥ 35 Ncm. * Patient is in good general health with no systemic contraindications to implant surgery. * Patient is cooperative and available for the entire 6-month follow-up period Exclusion Criteria: * Pregnant and lactating females. * Heavy smokers (smoking ≥ 10 cigarettes per day). * Patients with poor oral hygiene. * Patients with occlusal or malalignment problems. * Patients with parafunctional habits (e.g., bruxism).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immediate dental implant placement are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

capillary malformation-arteriovenous malformation syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Immediate dental implant placement

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Dentistry - Ain Shams University

    Cairo, 11566, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.